You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Bortezomib in Multiple Myeloma and Lymphoma

Version: 2 ID: 6-18 juin 2016
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
C.T. Kouroukis, D. Reece, F.G. Baldassarre, A.E. Haynes, K. Imrie, M. Cheung , Hematology Disease Site Group

Guideline Objective

To provide recommendations for the use of bortezomib alone or in combination with other agents in patients with multiple myeloma, or lymphoma, including Waldenström’s macroglobulinemia.

Patient Population

Adult patients with MM or lymphoma of any type, stage, histology, or performance status.

Intended Guideline Users

  • Healthcare practitioners treating patients with MM, or lymphoma, including WM.
  • Policy makers involved in the planning of treatment and the financing of drugs for MM, or lymphoma (including WM).

Research Question(s)

  1. In patients with multiple myeloma (MM), or lymphoma, including Waldenström’s macroglobulinemia (WM), what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (e.g., time-to-progression (TTP)), response duration, or response rate?
  2. What is the toxicity associated with the use of bortezomib?
  3. Which patients are more or less likely to benefit from treatment with bortezomib?
pdf download Full Report (PDF) (2.98 Mo)